Developing vaccines to prevent Hepatitis C virus infection
Rational design and efficacy testing of vaccines against HCV
This study is working on a new vaccine to help protect people from Hepatitis C, a virus that can cause serious liver problems, by focusing on parts of the virus that can boost the immune system's ability to fight it off.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Maryland, College Park NIH-funded |
| Lab location | 1 site (College Park, United States) |
| Project ID | NIH-11074583 on NIH RePORTER |
What this research studies
This research focuses on creating an effective vaccine against Hepatitis C virus (HCV), which affects millions globally and can lead to severe liver diseases. The team is investigating a specific part of the virus, known as the E1E2 glycoproteins, to design a vaccine that can stimulate the immune system to produce broadly neutralizing antibodies. By using innovative methods to present these viral components, they aim to enhance both B and T cell immune responses, which are crucial for controlling HCV infection. The ultimate goal is to provide a preventive solution that could significantly reduce the burden of HCV-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of Hepatitis C infection, including those with high exposure to the virus.
Not a fit: Patients who are already infected with Hepatitis C and are seeking treatment may not benefit from this vaccine-focused research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that prevents Hepatitis C infection and its associated severe liver diseases.
How similar studies have performed: Previous research has shown promise in developing vaccines targeting similar viral infections, indicating potential for success in this novel approach.
Where this research is happening
College Park, United States
- Univ of Maryland, College Park — College Park, United States (Active)
Researchers
- Principal investigator: Fuerst, Thomas R — Univ of Maryland, College Park
- Study coordinator: Fuerst, Thomas R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.